Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

European Psychiatry

Volumn 24, Issue 5, 2009, Pages 287-296

  Olivares, J M ^a   Rodriguez Morales, A ^b   Diels, J ^c   Povey, M ^d   Jacobs, A ^e   Zhao, Z ^e   Lam, A ^e  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b Janssen Cilag ^*  (Spain)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d SGS Medisearch International NV   (Belgium)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antipsychotic medication; Observational study; Risperidone long acting injection; Schizophrenia; Treatment retention

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE REGISTRY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SPAIN; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; LONG-TERM CARE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT READMISSION; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REGISTRIES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 65649114856     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2008.12.002     Document Type: Article

References (35)

1. ®) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res (2008) E-pub
2. Adams C.E., Fenton M.K., Quraishi S., and David A.S. Systematic meta-analysis of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179 (2001) 290-299
3. Beauclair L., Chue P., McCormick J., Camacho F., Lam A., and Luong D. Impact of risperidone long-acting injectable on hospitalization and medication use in Canadian patients with schizophrenia. J Med Econ 10 (2007) 427-442
4. Bhanji N.H., Chouinard G., and Margolese H.C. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 14 (2004) 87-92
5. Black N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 312 (1996) 1215-1218
6. Chue P. Long-acting risperidone injection. Efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat (2007) E-pub
7. Chue P., Eerdekens M., Augustyns I., Lauchaux B., Molcan P., Eriksson L., et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15 (2005) 111-117
8. Chue P., Llorca P., Duchesne I., Leal A., Rosillon D., and Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 5 (2005) 266-274
9. Davies L.M., and Drummond M.F. Economics and schizophrenia: the real cost. Br J Psychiatry 25 Suppl. (1994) 18-21
10. Davis J.M., Matalon L., Watanabe M.D., Blake L., and Matalon L. Depot antipsychotic drugs: place in therapy. Drugs 47 (1994) 741-743
11. Endicott J., Spitzer J., Fleiss J., and Cohen J. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33 (1976) 766-771
12. Fleischhacker W.W., Eerdekens M., Karcher K., Remington G., Llorca P.M., Chrzanowski W., et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64 (2003) 1250-1257
13. Gharabawi G.M., Gearhart N.C., Lasser R.A., Mahmoud R.A., Zhu Y., Mannaert E., et al. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry 6 (2007) 3
14. Guy W. Clinical global impression. In: Rush A.J. (Ed). Handbook of psychiatric measures (2000), American Psychiatric Association, Washington, DC 100-102
15. Haro J.M., Suarez D., Novick D., Brown J., Usall J., Naber D., et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17 (2007) 235-244
16. Hofer A., Hummer M., Huber R., Kurz M., Walch T., and Fleischhacker W.W. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 20 (2000) 699-702
17. Kane J.M., Aguglia E., Altamura A.C., Ayuso Gutierrez J.L., Brunello N., Fleischhacker W.W., et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8 (1998) 55-66
18. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., and Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160 (2003) 1125-1132
19. Kikkert M.J., Schene A.H., Koeter M.W., Robson D., Born A., Helm H., et al. Medication adherence in schizophrenia: exploring patients', carers' and professionals' views. Schizophr Bull 32 (2006) 786-794
20. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., and Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63 (2002) 892-909
21. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
22. Medori R, Wapenaar R, de Arce R, Rouillon F, Gaebel W, Cordes J, et al. Relapse prevention and effectiveness in schizophrenia with risperidone long-acting injectable (RLAI) versus quetiapine. Presented at the annual meeting of the American Psychiatric Association, 3-7 May 2008, Washington DC, USA.
23. Mohl A., Westlye K., Opjordsmoen S., Lex A., Schreiner A., Benoit M., et al. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 19 5 Suppl. (2005) 22-31
24. Möller H.J., Llorca P.M., Sacchetti E., Martin S.D., Medori R., Parellada E., et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20 (2005) 121-130
25. NICE (National Institute for Clinical Excellence, UK). Schizophrenia: full national clinical guideline on core interventions in primary and secondary care. Available at . Schizophrenia full guideline; 2003. p. 68 and 228.
26. Olivares JM, Peuskens J, Pecenak J, Tuma I, Van Kooten M, Eriksson L, et al. Treatment retention with risperidone long acting injection (RLAI) in European patients with schizophrenia: 12-month interim results from electronic Schizophrenia Treatment Adherence Registry (e-STAR). International Society for Pharmacoeconomics and Outcomes Research, 10th annual European Congress, 20-23 October 2007, Dublin, Ireland. Abstract PMH9.
27. Olivares J.M., Rodriguez-Martinez A., Buron J.A., Alonso-Escolano D., and Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia. A 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 6 (2008) 41-53
28. Robinson D., Woerner M.G., Pollack S., and Lerner G. Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol 16 (1996) 170-176
29. Taylor D.M., Young C., and Patel M. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 9 (2006) 685-694
30. Thornly B., and Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. Br Med J 317 (1998) 1181-1184
31. Turner M., Eerdekens E., Jacko M., and Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 19 (2004) 241-249
32. Valenstein M., Copeland L.A., Blow F.C., McCarthy J.F., Zeber J.E., Gillon L., et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 40 (2002) 630-639
33. Valenstein M., Blow F.C., Copeland L.A., McCarthy J.F., Zeber J.E., Gillon L., et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 30 (2004) 255-264
34. Watt D.C., Katz K., and Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 13 (1983) 663-670
35. Young J.L., Zonana H.V., and Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 14 (1986) 105-122